Osimertinib

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

Retrieved on: 
Wednesday, March 6, 2024
Glioblastoma, NSCLC, Diabetes, Lung, Lung cancer, Metabolism, EGFR, Osteosarcoma, MD, Neoplasm, FDA, Cancer, Glycolysis, Food, Growth, Anaplastic lymphoma kinase, Pembrolizumab, AACR, Cell, Apoptosis, Date, Osimertinib, Agonal respiration, Mitochondrion, Breast, University, Nanoparticle, Food and Drug Administration, NPRL2, Patient, ATP, Clinical trial, Gene, Disease, TUSC2, Trial of the century, Mesothelioma, Research, ALK, Vaccine

AUSTIN, Texas, March 6, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators will present at the upcoming 2024 American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024 in San Diego, California. The collaborators will present positive preclinical data from studies of its lead product candidate, Reqorsa® Immunogene Therapy (quaratusugene ozeplasmid), as well as NPRL2 gene therapy, which both utilize the Company's non-viral Oncoprex® Delivery System for the treatment of lung cancer.

Key Points: 
  • The collaborators will present positive preclinical data from studies of its lead product candidate, Reqorsa® Immunogene Therapy (quaratusugene ozeplasmid), as well as NPRL2 gene therapy, which both utilize the Company's non-viral Oncoprex® Delivery System for the treatment of lung cancer.
  • In this humanized mouse model, researchers investigated the anti-tumor immune responses to NPRL2 gene therapy in pembrolizumab resistant KRAS/STK11mt NSCLC.
  • "Today's bolus of compelling data validates the potential of REQORSA and the ONCOPREX Delivery System as innovative cancer treatments.
  • We look forward to continuing to evaluate the ONCOPREX Delivery System using both REQORSA and NPRL2 as potential treatments for lung cancer."

Ocean Biomedical (NASDAQ: OCEA) Announces Positive Preclinical Oncology Data for VRON-0300, Presented at SITC 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion Therapeutics

Retrieved on: 
Tuesday, November 14, 2023
Yale University, Lung, Canadian Tire money, Brain, Research, AstraZeneca, Therapy, Joint venture, IND, Non-small-cell lung cancer, Disease, Clinical trial, Osimertinib, Patient, HBV, International joint venture, Immunotherapy, Animal, Neoplasm, TKI, Lung cancer, MD, Person, Infection, NSCLC, Human, SITC, BioRxiv, Malaria, Society, EGFR, Brown University Graduate School, Fibrosis, Pharmaceutical industry, Vaccine, CHI3L1, Cancer, Ocean, Virus

These new data demonstrate complete and highly reproducible tumor clearance, and protection upon tumor rechallenge, months after animals cleared their initial tumors.

Key Points: 
  • These new data demonstrate complete and highly reproducible tumor clearance, and protection upon tumor rechallenge, months after animals cleared their initial tumors.
  • VRON-0300 IND-enabling activities are underway, with the goal of filing its first IND within the next 9 months.
  • Virion Therapeutics is developing novel immunotherapies that utilize proprietary genetically encoded checkpoint modifiers (CPMs) to enhance and broaden CD8+ T cells responses.
  • Preclinical studies using CPMs have shown consistent and extraordinary immune responses and clinical activity in different diseases.

New demonstration of the predictive power of an in silico clinical trial in oncology

Retrieved on: 
Monday, November 13, 2023
NGC 5286, TTP, Risk, Clinical trial, QSP, ESMO, Patient, Congress, CNRS, Amivantamab, Lung cancer, Death, Oncology, Hospices Civils de Lyon, HIV disease progression rates, Quantitative systems pharmacology, NSCLC, Pharmaceutical industry, Osimertinib, Janssen

These predictive findings were shared with the Janssen-Cilag France team a week in advance of the trial results being unveiled at the 2023 ESMO conference.

Key Points: 
  • These predictive findings were shared with the Janssen-Cilag France team a week in advance of the trial results being unveiled at the 2023 ESMO conference.
  • Prof. Michaël Duruisseaux was involved as an investigator, but not in the steering committee and was not informed of the non-public data from the trial.
  • Employing such techniques in the future will enable us to establish better clinical trial designs," commented Prof. Duruisseaux.
  • Novadiscovery provides its jinkō clinical trials simulation platform to biotech and pharma companies, academic research centers and university hospitals.

J INTS BIO Gives Presentation of Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, at ESMO Asia 2023

Retrieved on: 
Tuesday, December 5, 2023
Safety, ESMO, Patient, Osimertinib, Pharmacokinetics, Index, Trial of the century, MTD, Infrared spectroscopy correlation table, Mutation, EGFR, NSCLC, Pharmaceutical industry, Vaccine

SEOUL, South Korea, Dec. 5, 2023 /PRNewswire/ -- J INTS BIO announced that early results of the Phase 1/2 study of its novel, orally administered 4th generation EGFR-TKI 'JIN-A02' were presented at the ESMO Asia 2023 conference held in Singapore from 1st to 3rd December 2023.

Key Points: 
  • SEOUL, South Korea, Dec. 5, 2023 /PRNewswire/ -- J INTS BIO announced that early results of the Phase 1/2 study of its novel, orally administered 4th generation EGFR-TKI 'JIN-A02' were presented at the ESMO Asia 2023 conference held in Singapore from 1st to 3rd December 2023.
  • 'JIN-A02', a 4th generation EGFR-TKI, is a substance that selectively binds to C797S, a mutation that leads to resistance to 3rd generation EGFR-TKIs (Osimertinib, Lazertinib), a treatment for EGFR+ NSCLC.
  • During ESMO Asia, the safety and PK results for the first two cohorts of patients recruited in Part A (Dose Escalation) of the clinical study were presented.
  • According to J INTS BIO, the clinical study is progressing well and recruitment has been unexpectedly successful with no unnecessary delays between the cohorts.

J INTS BIO Gives Presentation of Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, at ESMO Asia 2023

Retrieved on: 
Tuesday, December 5, 2023
Safety, ESMO, Patient, Multimedia, Osimertinib, Pharmacokinetics, Index, Trial of the century, MTD, Infrared spectroscopy correlation table, Mutation, EGFR, NSCLC, Pharmaceutical industry, Vaccine

SEOUL, South Korea, Dec. 5, 2023 /PRNewswire/ -- J INTS BIO announced that early results of the Phase 1/2 study of its novel, orally administered 4th generation EGFR-TKI 'JIN-A02' were presented at the ESMO Asia 2023 conference held in Singapore from 1st to 3rd December 2023.

Key Points: 
  • SEOUL, South Korea, Dec. 5, 2023 /PRNewswire/ -- J INTS BIO announced that early results of the Phase 1/2 study of its novel, orally administered 4th generation EGFR-TKI 'JIN-A02' were presented at the ESMO Asia 2023 conference held in Singapore from 1st to 3rd December 2023.
  • 'JIN-A02', a 4th generation EGFR-TKI, is a substance that selectively binds to C797S, a mutation that leads to resistance to 3rd generation EGFR-TKIs (Osimertinib, Lazertinib), a treatment for EGFR+ NSCLC.
  • It has demonstrated strong efficacy in preclinical studies, and the results have already been presented at several academic conferences.
  • According to J INTS BIO, the clinical study is progressing well and recruitment has been unexpectedly successful with no unnecessary delays between the cohorts.

Ocean Biomedical Announces Newly Published Findings Demonstrating Ability to Restore Treatment Sensitivity to AstraZeneca’s Leading Lung Cancer Drug After Resistance Has Formed, and Enhanced Tumor Suppression in EGFR-Mutation Lung Cancers

Retrieved on: 
Tuesday, October 3, 2023
Yale University, BioRxiv, RI, FRG, Osimertinib, Lung cancer, TUNEL, TKI, Research, Targeted therapy of lung cancer, Cell, Immunotherapy, AstraZeneca, Glioblastoma, Preprint, Gefitinib, Patient, EGFR, Growth, Neoplasm, Salvage therapy, Pharmaceutical industry, Vaccine, Dietary supplement, Medical imaging, Ocean Biomedical, CHI3L1, NSCLC, Cancer

Providence, RI, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA) announced today that its cancer-targeting immunotherapy antibody candidate has demonstrated effective tumor reduction against an aggressive subset of Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutations. These research findings, which may be the most important Ocean Biomedical has announced to date, generated by Ocean’s Scientific Co-founder Dr. Jack A. Elias and colleagues from Yale University and Brown University, and first published as a preprint last week in bioRxiv, are the first to uncover the role of Chitinase 3-like-1 (CHI3L1) in the pathogenesis of EGFR-mutant cancers, with potential applications not just in NSCLC, but in all EGFR-mutant cancers, including glioblastoma and colon cancer.

Key Points: 
  • Additionally, the findings demonstrate a stunning ability to restore therapeutic sensitivity to current tyrosine kinase inhibitor (TKI) therapies after resistance sets in, including the third-generation TKI, Osimertinib (marketed as Tagrisso by AstraZeneca).
  • In 2022, AstraZeneca’s top pharmaceutical product by revenue was Tagrisso, a medication used in the treatment of non-small-cell lung carcinomas.
  • Non-Small Cell Lung Cancer (NSCLC) is a leading cause of cancer deaths globally, accounting for 85% of all lung cancers.
  • The EGFR-mutant lung cancer is found in 30%-50% of NSCLC patients with Asian heritage and 10%-20% of patients with Caucasian backgrounds.

Lung Cancer Therapies Market to Amplify Significantly over 2022-2029 - Brandessence Market Research

Retrieved on: 
Monday, May 29, 2023
Smoker, Atezolizumab, Complex conjugate, Lung cancer, Tobacco, Alectinib, Cough, Hospital, Acquisition, Patient, Investment, EGFR, Diffuse large B-cell lymphoma, Risk, Eli Lilly and Company, Spacecraft, Health, Air pollution, Virus, Disease, ALK, Therapy, Crizotinib, Entrectinib, Research, Paclitaxel, Boehringer Ingelheim, ARIAD Pharmaceuticals, Growth, Pembrolizumab, Smoking, Erlotinib, Docetaxel, Gas, Cancer, Osimertinib, Chest pain, Traction, Blood, Immune system, ROS1, Trastuzumab emtansine, Teva Pharmaceuticals, Radiation, Pfizer, Bristol Myers Squibb, AstraZeneca, Lung, Novartis, Smoke, Nivolumab, Pharmaceutical industry, Renewable energy, Vaccine, Bayer, Genentech, Talimogene laherparepvec

With rapid evolution in the field of medical research, numerous therapies aimed at treating lung cancer have been developed.

Key Points: 
  • With rapid evolution in the field of medical research, numerous therapies aimed at treating lung cancer have been developed.
  • The business intelligence report on Lung Cancer Therapies Market by Brandessence Market Research is curated with an aim to provide the industry participants with a succulent overview of this industry.
  • By treatment, the chemotherapy segment is projected to amass notable gains due to its efficacy in treating lung cancer.
  • The Lung Cancer Therapies Market is anticipated to garner significant returns over the estimated timeline of 2022-2029.

Pia Baumann takes up her position as Chief Medical Officer

Retrieved on: 
Tuesday, February 21, 2023
CMO, Karolinska University Hospital, SMAC, Pia, Drug development, Patient, Osimertinib, Nasdaq Stockholm, Takeda, ARIAD Pharmaceuticals, Partnership, MD, Karolinska Institute, AstraZeneca, Market capitalization, Incyte, Cancer, Pharmaceutical industry, Medivir

STOCKHOLM, Feb. 21, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that the company's new Chief Medical Officer (CMO) Pia Baumann took up her position.

Key Points: 
  • STOCKHOLM, Feb. 21, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that the company's new Chief Medical Officer (CMO) Pia Baumann took up her position.
  • Pia Baumann, an MD specialized in oncology who earned her Ph.D. at Karolinska Institute, has substantial experience in drug development in the cancer field.
  • Pia most recently held a position at AstraZeneca as Vice President Medical with global responsibility for the company's Tagrisso and Lung Cancer franchise.
  • "I am very pleased that Pia now has taken up the role as Chief Medical Officer.

Medivir recruits Pia Baumann as new Chief Medical Officer

Retrieved on: 
Monday, November 21, 2022
Karolinska Institute, MD, Takeda, Partnership, Incyte, AstraZeneca, Cancer, Karolinska University Hospital, Pia, Patient, SMAC, ARIAD Pharmaceuticals, Market capitalization, HCC, CMO, Drug development, Osimertinib, Liver cancer, Nasdaq Stockholm, Pharmaceutical industry, Medivir

STOCKHOLM, Nov. 21, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that Pia Baumann has been recruited as its new Chief Medical Officer (CMO).

Key Points: 
  • STOCKHOLM, Nov. 21, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that Pia Baumann has been recruited as its new Chief Medical Officer (CMO).
  • Pia Baumann, who is an MD specialized in oncology and earned her Ph.D. at Karolinska Institute, has substantial experience in drug development in the cancer field.
  • Pia most recently held a position at AstraZeneca as Vice President Medical with global responsibility for the company's Tagrisso and Lung Cancer franchise.
  • - I am very pleased that we managed to attract Pia to assume the position as Chief Medical Officer.

J INTS BIO, Novel Oral 4th Generation EGFR TKI 'JIN-A02' - Phase 1/2 IND approved by US FDA

Retrieved on: 
Friday, November 11, 2022
Traffic barrier, Permeability, Health, General of the branch, TKI, Drug discovery, Cancer, Brain, Cros, Patient, Recurrence, EGFR, Pharmaceutical industry, Vaccine, IND, Osimertinib, NSCLC

SEOUL, South Korea, Nov. 11, 2022 /PRNewswire/ -- J INTS BIO announced on November 9th that it had received approval from the US FDA for its Phase 1/2 clinical trial of its Novel Oral 4th Generation EGFR TKI 'JIN-A02' in patients with advanced non-small cell lung cancer (NSCLC).

Key Points: 
  • 'JIN-A02' is a Novel Orally administered 4th Generation EGFR TKI, which is highly selective and potent against NSCLC harboring C797S double or triple mutations, presenting in either cis or trans forms.
  • J INTS BIO is expecting the first patient to be recruited in the US before the end of the year.
  • 'JIN-A02' is a novel orally administered 4th Generation EGFR TKI targeting C797S mutations in NSCLC.
  • Although 1st, 2nd, and 3rd Generation EGFR TKIs have been used with some success, recurrence occurs in most patients including those on 3rd Generation TKIs such as Osimertinib.